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Simvastatin’s effects on survival and outcome in traumatic brain
injury patients: a comparative study
1,

1

2

3

Taraneh NAGHIBI *, Sara MADANI , Saideh MAZLOOMZADEH , Faramarz DOBAKHTI
Department of Anesthesiology and Critical Care Medicine, School of Medicine, Zanjan University of Medical Science, Zanjan, Iran
2
Department of Epidemiology, School of Medicine, Zanjan University of Medical Science, Zanjan, Iran
3
School of Pharmacy, Zanjan University of Medical Science, Zanjan, Iran

1

Received: 21.04.2014

Accepted/Published Online: 17.10.2014

Final Version: 05.01.2016

Background/aim: Mortality and morbidity still remain high in patients with traumatic brain injuries. Understanding the role of new
treatments in these patients is critical. The aim of this study was to determine the effect of simvastatin on survival and outcome in
traumatic brain injury patients.
Materials and methods: Forty-four patients were assigned to receive either simvastatin or a placebo. The serum interleukin-6 and
C-reactive protein levels were measured at the first 24 h and 48 h after trauma. All data, including the Glasgow Coma Scale score,
survival at discharge, length of intensive care unit stay, and duration of mechanical ventilation, were collected. The effect of simvastatin
on the collected data was then investigated.
Results: The Glasgow Coma Scale level at discharge was significantly higher in the simvastatin group. The overall mortality rate, duration
of mechanical ventilation, and length of intensive care unit stay were similar between the 2 groups. The C-reactive protein concentration
48 h after trauma was significantly lower in the simvastatin group, but there was no significant difference according to the interleukin-6
level 48 h after trauma between the 2 groups.
Conclusion: Simvastatin could be suggested as an adjunctive therapy in traumatic brain injury patients.
Key words: Simvastatin, traumatic brain injury, outcome, survival

1. Introduction
Traumatic brain injuries (TBIs) are a leading cause of
morbidity and mortality. Recent evidence suggests that
TBIs accounted for the majority of trauma deaths in
Europe. This situation is comparable in the United States
and is even worse in developing countries (1). Despite
recent improvements in the management of patients with
TBI in intensive care, mortality and morbidity in these
patients still remain high (2). Therefore, understanding
the role of new treatments in TBI outcome and mortality
is critical. An acute inflammatory response occurs within
the central nervous system (CNS) after severe TBI. This
response leads to brain damage following traumatic injury
(3). Many studies have revealed that the intracranial
inflammatory response in injured brain patients results in
an adverse outcome after head injury (4). After TBI several
cytokines and chemokines are released, which, if not
controlled, lead to secondary insults. The inflammatory
response within the injured brain can exacerbate the
damage following TBI. Many studies have demonstrated
* Correspondence: tnaghibi@zums.ac.ir

that limiting neuroinflammation is necessary for brain
repair. Based on this fact, the role of antiinflammatory
agents as a treatment drug in TBI has been investigated in
several studies (5).
Statins are characterized as reductase inhibitors and
have 3-hydroxy-3-methylglutaryl coenzyme activity.
A wide variety of advantages of statins has been proven
through recent research. Antiinflammatory actions, the
direct activation of heme oxygenase, direct interference in
leukocyte–endothelial interactions, and direct inhibition
of major histocompatibility complex class II are the effects
of statins that are independent of their lipid-lowering
ability (6).
Preinjury statin use and postinjury statin treatment
have been shown by many new studies to have beneficial
properties in patients suffering general trauma, TBI, and
burns. A well-designed clinical trial is required to determine
the therapeutic efficacy in improving outcomes in this
patient population (7). Many studies confirm the need
for randomized, controlled trials to verify the relationship
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between statin therapy and observed outcomes (6). In
this respect, a comparative study was designed to indicate
whether acute statin treatment following TBI was able to
reduce inflammatory cytokines and improve survival and
outcome in humans.
2. Materials and methods
2.1. Study design
After approval by the local ethics committee, 44 patients
were enrolled in this double-blind randomized clinical
trial study. The trial was registered with the Iranian
Registry of Clinical Trials (IRCT201305075363N3). Valid
informed written consent was obtained from all patients
or their relatives.
2.2. Study participants
Between June 2012 and August 2013, 44 patients who were
admitted to the intensive care unit (ICU) of our tertiary
health care institution within 24 h of head trauma were
screened for eligibility for enrollment in the trial. The
patients were divided into 2 groups, with 22 patients in
each group.
Patients were included if their age was older than
18 years; if they were not receiving NSAIDs, statins, or
corticosteroid drugs; if they had no allergy to statins; if there
was no other kind of trauma (except for head trauma); and
if they had no history of autoimmune, cardiac, respiratory,
neuromuscular, hepatic, or renal diseases.
Exclusion criteria were sepsis during the first 72 h of
admittance and if patients did not survive for at least 72 h
after admittance.
2.3. Randomization and blinding
Patients who met the inclusion criteria were randomly
assigned to receive either simvastatin (Hakim, 20 mg,
tablet) at a dose of 80 mg on the first day followed by 40
mg daily, or a placebo (lactose).
The patients were allocated to 1 of the 2 groups
according to a randomization code list in a randomly
permuted block design generated using a computer
program. Investigators were unaware of the treatment
groups.
2.4. Data extraction
Within the initial 24 h after the head trauma, age, sex,
chronic diseases, and severity of trauma according
to the Injury Severity Score (ISS) (8), Glasgow Coma
Scale (GCS), and Acute Physiology and Chronic Health
Evaluation II (APACHE II) score (9) were recorded. The
serum interleukin-6 (IL-6) and C-reactive protein (CRP)
levels were measured at the first 24 h and 48 h after trauma.
A previous study showed that IL-6 concentration increased
24 h after accidental trauma and continued to be present
for >5 days in injured patients (10). Another investigation
revealed that peak concentration of CRP occurred on day 2
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or 3 after trauma in most cases (11). Based on those results
the times were chosen for measuring the inflammatory
factors in this study.
As clinical features, all data of the GCS at discharge,
the outcome at discharge (dead or alive), the length of
ICU stay, and the duration of mechanical ventilation were
collected. Finally, the effect of simvastatin on the collected
data was investigated.
2.5. Biomarker selection and assays
Blood samples were obtained by venipuncture and the
cells were removed by centrifugation. Serum aliquots were
stored at –70 °C until they were analyzed. The level of IL-6
was measured by an ultrasensitive ELISA method and
CRP was measured via a high-sensitivity latex-enhanced
immunonephelometric assay. The minimum and upper
reference limit reported by the package insert for CRP was
0.2 and 5 mg/L.
2.6. Outcome
The primary outcome was ICU mortality. Secondary
outcomes included the GCS level at discharge, the ICU
length of stay, and the duration of mechanical ventilation.
2.7. Statistical analysis
SPSS 22 (SPSS Inc., Chicago, IL, USA) was used for the
statistical analyses. The Kolmogorov–Smirnov test was
used to evaluate the distribution of variables. Continuous
variables in 2 groups were compared using independent
sample t-test when data were normally distributed. The
Mann–Whitney U test was used when numerical data were
not normally distributed. Between-group comparisons
of proportions were performed by using the chi-square
test or the Fisher exact test, as appropriate. Results were
expressed as mean ± standard deviation (SD) and number
(percentage), as appropriate. Significance was defined as a
P-value of less than 0.05.
3. Results
3.1. Patient characteristics
Forty-four patients were enrolled in this prospective,
randomized study. One patient was not included due to his
drug history. Of the 43 patients, 22 received simvastatin
and 21 received a placebo. As shown in Table 1, patient
characteristics were comparable in terms of age, sex, ISS
score, APACHE II score, GCS score, and CRP and IL-6
levels upon admission (P > 0.05).
3.2. Biomarker analysis
The CRP concentration 48 h after trauma was statistically
significantly different between the 2 groups. Values in the
statin group were significantly lower than in the placebo
group (P = 0.042). Analyzing the CRP concentration
changes according to treatment arm shows that patients
treated with simvastatin had a significant reduction in
CRP level after 48 h of therapy (P < 0.001). CRP level after
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Table 1. Baseline characteristics of patients on statin therapy and placebo therapy.
Statin group
(n = 22)

Placebo group
(n = 21)

Age in years (mean ± SD)

38.3 ± 16.5

37.4 ± 17.5

Male sex, no. (%)

19 (86.4)

20 (95.2)

ISS, mean ± SD

26.7 ± 10.2

25.5 ± 8.7

APACHE II, mean ± SD

14.2 ± 6.6

14.8 ± 6.8

GCS, mean ± SD

6.6 ± 2.5

7.6 ± 2.9

CRP level mg/L, mean ± SD

77 ± 12.3

89 ± 45.3

IL-6 level pg/mL, mean ± SD

159.9 ± 65.7

145.1 ± 57.38

There was no statistically significant difference between groups (P > 0.05).
SD: Standard deviation, ISS: Injury Severity Score, APACHE II: Acute Physiology and
Chronic Health Evaluation II, GCS: Glasgow Coma Scale, CRP: C-reactive protein,
IL-6: interleukin-6.

48 h of trauma was increased in the placebo group, but this
change was not statistically significant (P = 0.192).
The IL-6 level 48 h after trauma in the simvastatin
group was lower than that of the control group; however,
there was no statistically significant difference between
the 2 groups according to the IL-6 level 48 h after trauma
(P = 0.55). Analyzing the IL-6 concentration changes in
the simvastatin group shows that patients treated with
simvastatin had a significant reduction in IL-6 level after
48 h of therapy (P < 0.001), but this significant reduction
was not observed in the placebo group (P = 0.067).
3.3. Outcome
The overall ICU mortality rate, the duration of mechanical
ventilation, and the length of ICU stay were similar
between the groups (Table 2).
When the GCS score at discharge was compared with
GCS at admission, there was an increase in both groups;
however, the GCS score at discharge was significantly

higher in the simvastatin group (Table 2).
4. Discussion
In animal studies the beneficial effect of statin treatment
after TBI has been shown in several studies. Wang et al.
showed that in adult rats following experimental TBI
simvastatin could attenuate the activation of cerebral
vascular endothelial inflammatory response and decrease
the loss of neurological function and brain tissue (12). In
another animal study, the positive effect of simvastatin
combined with an antioxidant was demonstrated as
neuroprotective in experimental TBI (13).
The beneficial effect of statin treatment after TBI is
probably true in humans as well as in animals (14). Our
study presents preliminary data that are in agreement
with this theory. In this study, TBI patients treated with
simvastatin showed higher GCS scores at discharge
compared with the control group. The reason for this

Table 2. Outcome of the included patients.
Outcome

Statin group
(n = 22)

Placebo group
(n = 21)

P-value

ICU mortality, no. (%)

1 (4.5)

5 (23.8)

0.95

GCS at discharge, mean ± SD

13.2 ± 2.7

10.8 ± 4.9

0.004*

Duration of mechanical ventilation, days, mean ± SD

4.5 ± 2.3

5.7 ± 3.4

0.15

Length of ICU stay, days, mean ± SD

7.1 ± 3.2

6.8 ± 4.1

0.135

*Statistically significant difference between groups (P < 0.05).
SD: Standard deviation, GCS: Glasgow Coma Scale, ICU: intensive care unit.
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finding can be related to the antiinflammatory effect
of statins on secondary injury mechanisms after TBI.
Antiinflammatory and neuroprotective effects of statins
have been proven by several preclinical studies. Béziaud
et al. demonstrated in a randomized study that simvastatin
reduced cerebral edema in rats with TBI by preserving
damage to tight junctions and neutrophil infiltration into
the parenchyma, which results in preserving the blood–
brain barrier integrity (15). The neuroprotective effects
of statins have been shown in many preclinical models as
well as in animal studies with TBI (16). The favorable effect
of statins in brain injury has been recently investigated in a
few clinical studies. In a double-blind randomized clinical
trial involving 36 TBI patients, the authors showed that
statins may induce an antiinflammatory effect, and may
promote recovery after TBI and reduce disability scores
compared with a placebo group (14). In addition, TapiaPérez et al. assessed the continued use of statins after
acute intracranial hemorrhage and showed that it could
be associated with early neurological improvement (17).
The results of these studies could explain the reason for the
better GCS score at discharge in the simvastatin group in
the present study.
Several investigations have shown the favorable effects
of statin therapy on mortality in critically ill patients.
Reduction of hospital mortality with statin therapy during
ICU stay was shown by a cohort study in a tertiary ICU
(6).
In another cohort study, Christensen et al. reported
that preadmission statin use was associated with reduced
risk of death following intensive care (18).These findings
are inconsistent with present study, in which there was
no significant difference in the mortality between the 2
groups. This disagreement with the findings of our study
may be explained by differences in study design, patient
population, statin types, and statin doses.
IL-6 and CRP levels were also measured as inflammatory
biomarkers at ICU admission and 48 h after TBI. In a
double-blind placebo-controlled randomized clinical trial,
Novack et al. reported that statin therapy may be associated
with a reduction in the levels of inflammatory cytokines
in patients with acute bacterial infections (19). A similar
finding was noted in the present study, in which IL-6 levels
decreased significantly at 48 h after TBI in the statin group

compared to the placebo group. Another inflammation
biomarker that has shown the antiinflammatory effect
of simvastatin in TBI patients was CRP level changes. In
this study, the CRP concentration 48 h after trauma in the
statin group was significantly lower than that in the placebo
group. These findings show the favorable effect of statins
in TBI patients. Based on previous findings, circulating
cytokines released as a result of an inflammatory response
can cross the blood–brain barrier and activate quiescent
microglia or cause an exaggerated inflammatory response
in primed microglia. Therefore, statins might have
changed the pathophysiologic response of the CNS to the
inflammation in patients suffering TBI (20).
In this study, patients in the intervention and control
groups did not have significantly different lengths of ICU
stay or durations of mechanical ventilation. A similar
finding was noted by Makris et al. in a randomized
controlled trial in which they suggested that oral pravastatin
in the treatment of ICU patients has no significant effect
on the length of ICU stay or the duration of mechanical
ventilation (21).
These findings suggest that statins may be useful as an
adjunctive therapy in critically ill patients. In this respect,
our results support the findings of previous studies
suggesting that statins may favorably affect the course of
critically ill patients.
The main limitation of this study was that it was
carried out in a single institute and only on patients of
the same race. Furthermore, the sample size was small. It
is recommended that other researchers should carry out
larger trials.
In conclusion, a significant difference in the GCS score
between the 2 groups was observed, which suggests that this
is the most significant marker of morbidity in patients with
brain injury; however, there was no significant difference in
the length of ICU stay, duration of mechanical ventilation,
or mortality in patients. In addition, the inflammatory
biomarkers in the intervention group had a significant
reduction in comparison with the control group, which
could reduce secondary damage following inflammation.
Based on these findings, it could be suggested that statins
may be useful as an adjunctive therapy in patients with
head trauma. For more confirmation, the authors suggest
additional clinical trials with larger sample sizes.
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